View ValuationBioGaia 향후 성장Future 기준 점검 4/6BioGaia (는) 각각 연간 18.2% 및 10.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 18.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 37.2% 로 예상됩니다.핵심 정보18.2%이익 성장률18.16%EPS 성장률Biotechs 이익 성장22.8%매출 성장률10.8%향후 자기자본이익률37.20%애널리스트 커버리지Low마지막 업데이트08 May 2026최근 향후 성장 업데이트공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.공시 • Oct 17BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022BioGaia AB (publ) provided earnings guidance for the third quarter of 2022. For the third quarter, sales are preliminarily estimated at SEK 258 million (174), an increase of 48%. The operating profit for the third quarter is preliminarily estimated at SEK 94 million (67), an increase of 40%.공시 • Jul 14Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022BioGaia AB (publ) provided earnings guidance for the second quarter of 2022. For the period, Sales are preliminarily estimated at SEK 288 million (203), up 42% and Operating profit is preliminarily estimated at SEK 101 million (69), up 46%.공시 • Apr 26BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022BioGaia AB (publ) provided earnings guidance for the first quarter of 2022. For the quarter, the company sales are preliminarily estimated at SEK 284 million. Operating profit is preliminarily estimated at SEK 95 million.모든 업데이트 보기Recent updates공시 • Feb 13BioGaia AB (publ), Annual General Meeting, May 07, 2026BioGaia AB (publ), Annual General Meeting, May 07, 2026.공시 • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).공시 • Oct 22+ 2 more updatesBioGaia AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026BioGaia AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 12, 2026공시 • Oct 13BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025공시 • Aug 22BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the BoardAt an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman.공시 • Jul 25Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025.공시 • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.공시 • Mar 21Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B)Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion). After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction.공시 • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.공시 • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).공시 • Dec 06BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTIONBioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation.Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023)Third quarter 2024 results: EPS: kr0.36 (down from kr1.01 in 3Q 2023). Revenue: kr304.0m (down 4.3% from 3Q 2023). Net income: kr36.6m (down 64% from 3Q 2023). Profit margin: 12% (down from 32% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Oct 22BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025Recent Insider Transactions • Sep 06Executive VP & CFO recently sold €996k worth of stockOn the 2nd of September, Alexander Kotsinas sold around 95k shares on-market at roughly €10.49 per share. This transaction amounted to 97% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Alexander's only on-market trade for the last 12 months.Reported Earnings • Jul 24Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023)Second quarter 2024 results: EPS: kr1.10 (up from kr0.80 in 2Q 2023). Revenue: kr384.1m (up 22% from 2Q 2023). Net income: kr111.0m (up 38% from 2Q 2023). Profit margin: 29% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.공시 • Jul 23BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025Reported Earnings • May 07First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023)First quarter 2024 results: EPS: kr1.21 (up from kr1.15 in 1Q 2023). Revenue: kr369.8m (up 1.1% from 1Q 2023). Net income: kr121.8m (up 5.1% from 1Q 2023). Profit margin: 33% (up from 32% in 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 26Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)Full year 2023 results: EPS: kr3.62 (down from kr3.70 in FY 2022). Revenue: kr1.30b (up 17% from FY 2022). Net income: kr365.4m (down 2.3% from FY 2022). Profit margin: 28% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Declared Dividend • Feb 12Dividend of kr6.90 announcedShareholders will receive a dividend of kr6.90. Ex-date: 8th May 2024 Payment date: 15th May 2024 Dividend yield will be 65%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (53% earnings payout ratio) but not covered by cash flows (185% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 19% over the next 2 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 08Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)Full year 2023 results: EPS: kr3.62 (down from kr3.70 in FY 2022). Revenue: kr1.30b (up 17% from FY 2022). Net income: kr365.4m (down 2.3% from FY 2022). Profit margin: 28% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.공시 • Feb 07+ 2 more updatesBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).공시 • Oct 22+ 1 more updateBioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024BioGaia AB (publ) announced that they will report first half, 2024 results on Jul 07, 2024Reported Earnings • Oct 22Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr317.7m (up 23% from 3Q 2022). Net income: kr101.5m (up 28% from 3Q 2022). Profit margin: 32% (up from 31% in 3Q 2022). The increase in margin was driven by higher revenue.공시 • Oct 19+ 1 more updateBioGaia AB (publ), Annual General Meeting, Apr 26, 2024BioGaia AB (publ), Annual General Meeting, Apr 26, 2024.공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.공시 • Sep 26Biogaia AB (Publ) Appoints Theresa Agnew as CEOBioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.공시 • Sep 02BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in SwedenBioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199.공시 • Aug 03BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.Reported Earnings • Jul 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr315.2m (up 9.4% from 2Q 2022). Net income: kr80.5m (up 2.5% from 2Q 2022). Profit margin: 26% (down from 27% in 2Q 2022). The decrease in margin was driven by higher expenses.공시 • Jul 06BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adultsA randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections.Board Change • May 15Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Director Niklas Ringby was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • May 07First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr365.8m (up 29% from 1Q 2022). Net income: kr115.9m (up 52% from 1Q 2022). Profit margin: 32% (up from 27% in 1Q 2022). The increase in margin was driven by higher revenue.공시 • May 06+ 2 more updatesBioGaia AB (Publ) Approves Dividend for 2022BioGaia AB (publ) at its AGM held on May 5, 2023 approved a dividend of SEK 1.45 per share for 2022, a grant of SEK 4.4 million to "The Foundation to Prevent Antibiotic Resistance" that was founded by BioGaia in 2017.Upcoming Dividend • May 01Upcoming dividend of kr2.90 per share at 2.8% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (2.4%).Reported Earnings • Mar 31Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)Full year 2022 results: EPS: kr3.70 (up from kr1.94 in FY 2021). Revenue: kr1.10b (up 41% from FY 2021). Net income: kr373.8m (up 90% from FY 2021). Profit margin: 34% (up from 25% in FY 2021). Post-clinical trial products Launched (during full year): 3 Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 05Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)Full year 2022 results: EPS: kr3.70 (up from kr1.94 in FY 2021). Revenue: kr1.10b (up 41% from FY 2021). Net income: kr373.6m (up 90% from FY 2021). Profit margin: 34% (up from 25% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공시 • Feb 03+ 1 more updateBioGaia AB (publ) Proposes Ordinary DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 5 May 2023 approves an ordinary dividend according to policy of SEK 1.45 (0.73) per share.Reported Earnings • Oct 22Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr257.7m (up 48% from 3Q 2021). Net income: kr79.5m (up 50% from 3Q 2021). Profit margin: 31% (in line with 3Q 2021). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 21% share price gain to €8.37, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €5.22 per share.공시 • Oct 17BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022BioGaia AB (publ) provided earnings guidance for the third quarter of 2022. For the third quarter, sales are preliminarily estimated at SEK 258 million (174), an increase of 48%. The operating profit for the third quarter is preliminarily estimated at SEK 94 million (67), an increase of 40%.Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €8.82, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 30x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.92 per share.Reported Earnings • Jul 25Second quarter 2022 earnings released: EPS: kr0.78 (vs kr0.54 in 2Q 2021)Second quarter 2022 results: EPS: kr0.78 (up from kr0.54 in 2Q 2021). Revenue: kr288.1m (up 42% from 2Q 2021). Net income: kr78.5m (up 44% from 2Q 2021). Profit margin: 27% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 9.2%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.공시 • Jul 14Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022BioGaia AB (publ) provided earnings guidance for the second quarter of 2022. For the period, Sales are preliminarily estimated at SEK 288 million (203), up 42% and Operating profit is preliminarily estimated at SEK 101 million (69), up 46%.공시 • May 08BioGaia AB (publ) Approves Extra DividendThe Annual General Meeting of BioGaia AB (publ) on 6 May 2022 voted to approve a dividend an extra dividend of SEK 11.29 per share.Reported Earnings • May 07First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr283.9m (up 41% from 1Q 2021). Net income: kr76.3m (up 51% from 1Q 2021). Profit margin: 27% (up from 25% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 37% growth forecast for the industry in Germany.Upcoming Dividend • May 02Upcoming dividend of kr14.92 per shareEligible shareholders must have bought the stock before 09 May 2022. Payment date: 13 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.5%).공시 • Apr 26BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022BioGaia AB (publ) provided earnings guidance for the first quarter of 2022. For the quarter, the company sales are preliminarily estimated at SEK 284 million. Operating profit is preliminarily estimated at SEK 95 million.공시 • Apr 06+ 1 more updateBioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022The board of directors of BioGaia AB (publ) proposed that the shareholders be paid a dividend of SEK 3.63 per share, resulting in a total dividend of SEK 14.92 per share, at its annual general meeting on 6 May 2022, with the record date 10 May 2022. The dividend is expected to be disbursed by Euroclear Sweden AB on 13 May 2022.Reported Earnings • Mar 31Full year 2021 earnings released: EPS: kr9.72 (vs kr10.07 in FY 2020)Full year 2021 results: EPS: kr9.72. Revenue: kr785.1m (up 5.1% from FY 2020). Net income: kr196.3m (up 9.2% from FY 2020). Profit margin: 25% (in line with FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 86% growth forecast for the pharmaceuticals industry in Germany.공시 • Feb 05+ 1 more updateBiogaia AB (Publ) Proposes Ordinary DividendThe board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on May 6, 2022 approves an ordinary dividend according to policy of SEK 3.63 per share. The Board further proposes a 5:1 split of common shares (class A and B shares).공시 • Feb 03BioGaia's Probiotic Reduces Inflammation in Patients with DiverticulitisA randomized, double-blind, placebo-controlled study with BioGaia's probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 was shown to reduce inflammation significantly more than placebo in patients with acute uncomplicated diverticulitis. Moreover, as hospitalization time was shorter in the probiotic group, the probiotic supplementation also had economic benefits. The study included 119 patients, 49 males and 70 females, diagnosed with acute uncomplicated diverticulitis. Mean age was 65 years. All patients were given fluids and bowel rest for 48 hours. Half of the group were additionally supplemented by Limosilactobacillus reuteri ATCC PTA 4659 for 10 days, while the other half were given a placebo. BioGaia's probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 has in experimental models shown strong anti-inflammatory properties, indicating potential positive effects in inflammatory conditions of the intestine. The now published study is the first randomized, double-blind, placebo-controlled study using this anti-inflammatory strain for acute uncomplicated diverticulitis without any antibiotic therapy. It is common, especially after the age of 40, to have small, bulging pouches in the lining of the digestive tract. The condition known as diverticulitis occurs when one or more of these pouches become inflamed or infected, something that can cause severe abdominal pain, but also fever, nausea, and changes in bowel habits.공시 • Jan 26BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1)BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites fourth quarter 2021 and screening began. The first patient was enrolled into OIC-1 in January 2022. BGP345A looks to treat constipation in patients receiving opioid therapy for prescribed pain treatment. Opioids are an essential option for chronic pain, primarily back pain, rheumatism or post-operative pain, where non-opioid multimodal drugs or physical therapy are not providing relief. Opioid use can lead to a number of side effects with Opioid-Induced Constipation (OIC) being the most common with a varying prevalance of 41-81%. Current first line therapy is the use of laxatives but at least 45% of patients are laxative refractory and continue to have motility issues. The approved study is a Phase II multi-centre study to assess the safety and preliminary efficacy of BGP345A and will take place in France.Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr173.8m (up 32% from 3Q 2020). Net income: kr52.8m (up 158% from 3Q 2020). Profit margin: 30% (up from 16% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Aug 13Second quarter 2021 earnings released: EPS kr2.71 (vs kr4.56 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr203.1m (down 17% from 2Q 2020). Net income: kr54.7m (down 31% from 2Q 2020). Profit margin: 27% (down from 32% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.공시 • Jul 03BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million.BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million on July 2, 2021. Upon completion, BioGaia becomes 100% shareholder of MetaboGen. BioGaia AB (publ) (OM:BIOG B) completed the acquisition of remaining 8% stake in MetaboGen AB on July 2, 2021.Recent Insider Transactions • Jun 01Vice President of RA & Legal recently bought €10k worth of stockOn the 27th of May, Marika Isberg bought around 250 shares on-market at roughly €40.52 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €19k more in shares than they have sold in the last 12 months.공시 • May 07Biogaia AB (Publ) Approves DividendThe Annual General Meeting of BioGaia AB (publ) held on 6 May 2021, approved the dividend of SEK 3.41 per share.Reported Earnings • May 06First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr202.0m (up 11% from 1Q 2020). Net income: kr50.4m (up 21% from 1Q 2020). Profit margin: 25% (up from 23% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Upcoming Dividend • Apr 30Upcoming dividend of kr3.41 per shareEligible shareholders must have bought the stock before 07 May 2021. Payment date: 14 May 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.1%). Higher than average of industry peers (0.5%).Reported Earnings • Apr 04Full year 2020 earnings released: EPS kr10.07The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr747.1m (down 2.8% from FY 2019). Net income: kr179.7m (down 4.1% from FY 2019). Profit margin: 24% (in line with FY 2019). Post-clinical trial products Launched (during full year): 18 Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year.Is New 90 Day High Low • Feb 20New 90-day low: €43.00The company is down 4.0% from its price of €44.70 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.41 per share.Recent Insider Transactions • Feb 12CEO & President recently bought €9.8k worth of stockOn the 4th of February, Isabelle Valerie Ducellier bought around 220 shares on-market at roughly €44.43 per share. This was the largest purchase by an insider in the last 3 months. Isabelle Valerie has been a buyer over the last 12 months, purchasing a net total of €56k worth in shares.Reported Earnings • Feb 06Full year 2020 earnings released: EPS kr10.07 (vs kr10.81 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr747.1m (down 2.8% from FY 2019). Net income: kr179.7m (down 4.1% from FY 2019). Profit margin: 24% (in line with FY 2019). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.5%. Over the next year, revenue is forecast to grow 4.6%, compared to a 80% growth forecast for the Biotechs industry in Germany.공시 • Nov 26BioGaia AB (publ) Elects Niklas Ringby as New Board MemberBioGaia AB (publ) announced at its Extraordinary General Meeting was held on 25 November 2020, the shareholders elected Niklas Ringby as new Board member.Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 19% share price gain to kr48.90, the stock is trading at a trailing P/E ratio of 44.8x, up from the previous P/E ratio of 37.6x. This compares to an average P/E of 30x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 62%.공시 • Oct 31BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion.BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion. Security Name: B Shares Security Type: Common Stock Securities Offered: 2,860,000 Price\Range: SEK 400Reported Earnings • Oct 24Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr193.8m, up 1.0% from the prior year. Total revenue was kr767.1m over the last 12 months, largely unchanged from the prior year.Analyst Estimate Surprise Post Earnings • Oct 24Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 29% at kr132.0m. Revenue is forecast to grow 18% over the next year, compared to a 301% growth forecast for the Biotechs industry in Germany.Valuation Update With 7 Day Price Move • Oct 19Market pulls back on stock over the past weekAfter last week's 21% share price decline to kr44.05, the stock is trading at a trailing P/E ratio of 37.6x, down from the previous P/E ratio of 47.9x. This compares to an average P/E of 36x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 57%.Is New 90 Day High Low • Oct 16New 90-day low: €43.55The company is down 17% from its price of €52.40 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.89 per share.Valuation Update With 7 Day Price Move • Oct 16Market pulls back on stock over the past weekAfter last week's 18% share price decline to kr43.55, the stock is trading at a trailing P/E ratio of 38.1x, down from the previous P/E ratio of 46.4x. This compares to an average P/E of 36x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 55%.공시 • Oct 05Biogaia Announces L. reuteri Protectis Reduces Pain in Children with Functional Abdominal PainIn a newly published systematic review and meta-analysis BioGaia AB (publ)'s L.reuteri Protectis (DSM 17938) was the only probiotic showing reduced pain intensity as well as an increased number of pain free days compared to placebo, in children with functional abdominal pain (FAP). Even if functional abdominal pain is a common gastrointestinal disorder, there are still no adequate treatment options available. The aim of the systematic review and meta-analysis was therefore to evaluate strain-specific probiotic effects on functional abdominal pain in children. The meta-analysis included nine studies, of which six were conducted with L. reuteri DSM 17938 and three with L. rhamnosus GG (LGG). The primary outcome, number of children with no symptoms at end of intervention, was however not reached.공시 • Aug 14+ 1 more updateBioGaia AB (publ) to Report First Half, 2021 Results on Aug 12, 2021BioGaia AB (publ) announced that they will report first half, 2021 results on Aug 12, 2021이익 및 매출 성장 예측DB:BGLA - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20282,074563540555112/31/20271,862504483494112/31/20261,66742343644813/31/20261,544332337341N/A12/31/20251,538333303307N/A9/30/20251,462316322325N/A6/30/20251,440287310315N/A3/31/20251,419310351357N/A12/31/20241,423351359373N/A9/30/20241,356337365393N/A6/30/20241,369402360394N/A3/31/20241,300371323379N/A12/31/20231,297365377426N/A9/30/20231,273437361396N/A6/30/20231,213415311342N/A3/31/20231,186413310324N/A12/31/20221,104374301319N/A9/30/20221,036273262284N/A6/30/2022952246286305N/A3/31/2022867222263273N/A12/31/2021785196215222N/A9/30/2021767196215220N/A6/30/2021725164201208N/A3/31/2021766188177190N/A12/31/2020747180205221N/A9/30/2020767194155184N/A6/30/2020802211155189N/A3/31/2020780193147185N/A12/31/2019768187N/A148N/A9/30/2019770192N/A160N/A6/30/2019778205N/A174N/A3/31/2019756207N/A176N/A12/31/2018742215N/A183N/A9/30/2018702206N/A223N/A6/30/2018675197N/A192N/A3/31/2018631181N/A181N/A12/31/2017615181N/A223N/A9/30/2017584179N/A201N/A6/30/2017562172N/A210N/A3/31/2017542163N/A198N/A12/31/2016535160N/A148N/A9/30/2016500138N/A115N/A6/30/2016480129N/A86N/A3/31/2016478130N/A108N/A12/31/2015483138N/A118N/A9/30/2015500130N/A100N/A6/30/2015474119N/A67N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BGLA 의 연간 예상 수익 증가율(18.2%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: BGLA 의 연간 수익(18.2%)이 German 시장(17.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: BGLA 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: BGLA 의 수익(연간 10.8%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: BGLA 의 수익(연간 10.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BGLA의 자본 수익률은 3년 후 37.2%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/12 05:39종가2026/06/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioGaia AB (publ)는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Christopher UhdeABG Sundal Collier SponsoredMattias HäggblomDanske BankKristofer Liljeberg-SvenssonDNB Carnegie
공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.
공시 • Oct 17BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022BioGaia AB (publ) provided earnings guidance for the third quarter of 2022. For the third quarter, sales are preliminarily estimated at SEK 258 million (174), an increase of 48%. The operating profit for the third quarter is preliminarily estimated at SEK 94 million (67), an increase of 40%.
공시 • Jul 14Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022BioGaia AB (publ) provided earnings guidance for the second quarter of 2022. For the period, Sales are preliminarily estimated at SEK 288 million (203), up 42% and Operating profit is preliminarily estimated at SEK 101 million (69), up 46%.
공시 • Apr 26BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022BioGaia AB (publ) provided earnings guidance for the first quarter of 2022. For the quarter, the company sales are preliminarily estimated at SEK 284 million. Operating profit is preliminarily estimated at SEK 95 million.
공시 • Feb 13BioGaia AB (publ), Annual General Meeting, May 07, 2026BioGaia AB (publ), Annual General Meeting, May 07, 2026.
공시 • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).
공시 • Oct 22+ 2 more updatesBioGaia AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026BioGaia AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 12, 2026
공시 • Oct 13BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025
공시 • Aug 22BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the BoardAt an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman.
공시 • Jul 25Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025.
공시 • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.
공시 • Mar 21Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B)Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion). After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction.
공시 • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.
공시 • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).
공시 • Dec 06BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTIONBioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation.
Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023)Third quarter 2024 results: EPS: kr0.36 (down from kr1.01 in 3Q 2023). Revenue: kr304.0m (down 4.3% from 3Q 2023). Net income: kr36.6m (down 64% from 3Q 2023). Profit margin: 12% (down from 32% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Oct 22BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025
Recent Insider Transactions • Sep 06Executive VP & CFO recently sold €996k worth of stockOn the 2nd of September, Alexander Kotsinas sold around 95k shares on-market at roughly €10.49 per share. This transaction amounted to 97% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Alexander's only on-market trade for the last 12 months.
Reported Earnings • Jul 24Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023)Second quarter 2024 results: EPS: kr1.10 (up from kr0.80 in 2Q 2023). Revenue: kr384.1m (up 22% from 2Q 2023). Net income: kr111.0m (up 38% from 2Q 2023). Profit margin: 29% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
공시 • Jul 23BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025
Reported Earnings • May 07First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023)First quarter 2024 results: EPS: kr1.21 (up from kr1.15 in 1Q 2023). Revenue: kr369.8m (up 1.1% from 1Q 2023). Net income: kr121.8m (up 5.1% from 1Q 2023). Profit margin: 33% (up from 32% in 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 26Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)Full year 2023 results: EPS: kr3.62 (down from kr3.70 in FY 2022). Revenue: kr1.30b (up 17% from FY 2022). Net income: kr365.4m (down 2.3% from FY 2022). Profit margin: 28% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Feb 12Dividend of kr6.90 announcedShareholders will receive a dividend of kr6.90. Ex-date: 8th May 2024 Payment date: 15th May 2024 Dividend yield will be 65%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (53% earnings payout ratio) but not covered by cash flows (185% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 19% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 08Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)Full year 2023 results: EPS: kr3.62 (down from kr3.70 in FY 2022). Revenue: kr1.30b (up 17% from FY 2022). Net income: kr365.4m (down 2.3% from FY 2022). Profit margin: 28% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
공시 • Feb 07+ 2 more updatesBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).
공시 • Oct 22+ 1 more updateBioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024BioGaia AB (publ) announced that they will report first half, 2024 results on Jul 07, 2024
Reported Earnings • Oct 22Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr317.7m (up 23% from 3Q 2022). Net income: kr101.5m (up 28% from 3Q 2022). Profit margin: 32% (up from 31% in 3Q 2022). The increase in margin was driven by higher revenue.
공시 • Oct 19+ 1 more updateBioGaia AB (publ), Annual General Meeting, Apr 26, 2024BioGaia AB (publ), Annual General Meeting, Apr 26, 2024.
공시 • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.
공시 • Sep 26Biogaia AB (Publ) Appoints Theresa Agnew as CEOBioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
공시 • Sep 02BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in SwedenBioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199.
공시 • Aug 03BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.
Reported Earnings • Jul 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr315.2m (up 9.4% from 2Q 2022). Net income: kr80.5m (up 2.5% from 2Q 2022). Profit margin: 26% (down from 27% in 2Q 2022). The decrease in margin was driven by higher expenses.
공시 • Jul 06BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adultsA randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections.
Board Change • May 15Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Director Niklas Ringby was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • May 07First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr365.8m (up 29% from 1Q 2022). Net income: kr115.9m (up 52% from 1Q 2022). Profit margin: 32% (up from 27% in 1Q 2022). The increase in margin was driven by higher revenue.
공시 • May 06+ 2 more updatesBioGaia AB (Publ) Approves Dividend for 2022BioGaia AB (publ) at its AGM held on May 5, 2023 approved a dividend of SEK 1.45 per share for 2022, a grant of SEK 4.4 million to "The Foundation to Prevent Antibiotic Resistance" that was founded by BioGaia in 2017.
Upcoming Dividend • May 01Upcoming dividend of kr2.90 per share at 2.8% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (2.4%).
Reported Earnings • Mar 31Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)Full year 2022 results: EPS: kr3.70 (up from kr1.94 in FY 2021). Revenue: kr1.10b (up 41% from FY 2021). Net income: kr373.8m (up 90% from FY 2021). Profit margin: 34% (up from 25% in FY 2021). Post-clinical trial products Launched (during full year): 3 Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 05Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)Full year 2022 results: EPS: kr3.70 (up from kr1.94 in FY 2021). Revenue: kr1.10b (up 41% from FY 2021). Net income: kr373.6m (up 90% from FY 2021). Profit margin: 34% (up from 25% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공시 • Feb 03+ 1 more updateBioGaia AB (publ) Proposes Ordinary DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 5 May 2023 approves an ordinary dividend according to policy of SEK 1.45 (0.73) per share.
Reported Earnings • Oct 22Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr257.7m (up 48% from 3Q 2021). Net income: kr79.5m (up 50% from 3Q 2021). Profit margin: 31% (in line with 3Q 2021). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 21% share price gain to €8.37, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €5.22 per share.
공시 • Oct 17BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022BioGaia AB (publ) provided earnings guidance for the third quarter of 2022. For the third quarter, sales are preliminarily estimated at SEK 258 million (174), an increase of 48%. The operating profit for the third quarter is preliminarily estimated at SEK 94 million (67), an increase of 40%.
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €8.82, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 30x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.92 per share.
Reported Earnings • Jul 25Second quarter 2022 earnings released: EPS: kr0.78 (vs kr0.54 in 2Q 2021)Second quarter 2022 results: EPS: kr0.78 (up from kr0.54 in 2Q 2021). Revenue: kr288.1m (up 42% from 2Q 2021). Net income: kr78.5m (up 44% from 2Q 2021). Profit margin: 27% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 9.2%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
공시 • Jul 14Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022BioGaia AB (publ) provided earnings guidance for the second quarter of 2022. For the period, Sales are preliminarily estimated at SEK 288 million (203), up 42% and Operating profit is preliminarily estimated at SEK 101 million (69), up 46%.
공시 • May 08BioGaia AB (publ) Approves Extra DividendThe Annual General Meeting of BioGaia AB (publ) on 6 May 2022 voted to approve a dividend an extra dividend of SEK 11.29 per share.
Reported Earnings • May 07First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr283.9m (up 41% from 1Q 2021). Net income: kr76.3m (up 51% from 1Q 2021). Profit margin: 27% (up from 25% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 37% growth forecast for the industry in Germany.
Upcoming Dividend • May 02Upcoming dividend of kr14.92 per shareEligible shareholders must have bought the stock before 09 May 2022. Payment date: 13 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.5%).
공시 • Apr 26BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022BioGaia AB (publ) provided earnings guidance for the first quarter of 2022. For the quarter, the company sales are preliminarily estimated at SEK 284 million. Operating profit is preliminarily estimated at SEK 95 million.
공시 • Apr 06+ 1 more updateBioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022The board of directors of BioGaia AB (publ) proposed that the shareholders be paid a dividend of SEK 3.63 per share, resulting in a total dividend of SEK 14.92 per share, at its annual general meeting on 6 May 2022, with the record date 10 May 2022. The dividend is expected to be disbursed by Euroclear Sweden AB on 13 May 2022.
Reported Earnings • Mar 31Full year 2021 earnings released: EPS: kr9.72 (vs kr10.07 in FY 2020)Full year 2021 results: EPS: kr9.72. Revenue: kr785.1m (up 5.1% from FY 2020). Net income: kr196.3m (up 9.2% from FY 2020). Profit margin: 25% (in line with FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 86% growth forecast for the pharmaceuticals industry in Germany.
공시 • Feb 05+ 1 more updateBiogaia AB (Publ) Proposes Ordinary DividendThe board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on May 6, 2022 approves an ordinary dividend according to policy of SEK 3.63 per share. The Board further proposes a 5:1 split of common shares (class A and B shares).
공시 • Feb 03BioGaia's Probiotic Reduces Inflammation in Patients with DiverticulitisA randomized, double-blind, placebo-controlled study with BioGaia's probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 was shown to reduce inflammation significantly more than placebo in patients with acute uncomplicated diverticulitis. Moreover, as hospitalization time was shorter in the probiotic group, the probiotic supplementation also had economic benefits. The study included 119 patients, 49 males and 70 females, diagnosed with acute uncomplicated diverticulitis. Mean age was 65 years. All patients were given fluids and bowel rest for 48 hours. Half of the group were additionally supplemented by Limosilactobacillus reuteri ATCC PTA 4659 for 10 days, while the other half were given a placebo. BioGaia's probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 has in experimental models shown strong anti-inflammatory properties, indicating potential positive effects in inflammatory conditions of the intestine. The now published study is the first randomized, double-blind, placebo-controlled study using this anti-inflammatory strain for acute uncomplicated diverticulitis without any antibiotic therapy. It is common, especially after the age of 40, to have small, bulging pouches in the lining of the digestive tract. The condition known as diverticulitis occurs when one or more of these pouches become inflamed or infected, something that can cause severe abdominal pain, but also fever, nausea, and changes in bowel habits.
공시 • Jan 26BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1)BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites fourth quarter 2021 and screening began. The first patient was enrolled into OIC-1 in January 2022. BGP345A looks to treat constipation in patients receiving opioid therapy for prescribed pain treatment. Opioids are an essential option for chronic pain, primarily back pain, rheumatism or post-operative pain, where non-opioid multimodal drugs or physical therapy are not providing relief. Opioid use can lead to a number of side effects with Opioid-Induced Constipation (OIC) being the most common with a varying prevalance of 41-81%. Current first line therapy is the use of laxatives but at least 45% of patients are laxative refractory and continue to have motility issues. The approved study is a Phase II multi-centre study to assess the safety and preliminary efficacy of BGP345A and will take place in France.
Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr173.8m (up 32% from 3Q 2020). Net income: kr52.8m (up 158% from 3Q 2020). Profit margin: 30% (up from 16% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 13Second quarter 2021 earnings released: EPS kr2.71 (vs kr4.56 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr203.1m (down 17% from 2Q 2020). Net income: kr54.7m (down 31% from 2Q 2020). Profit margin: 27% (down from 32% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
공시 • Jul 03BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million.BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million on July 2, 2021. Upon completion, BioGaia becomes 100% shareholder of MetaboGen. BioGaia AB (publ) (OM:BIOG B) completed the acquisition of remaining 8% stake in MetaboGen AB on July 2, 2021.
Recent Insider Transactions • Jun 01Vice President of RA & Legal recently bought €10k worth of stockOn the 27th of May, Marika Isberg bought around 250 shares on-market at roughly €40.52 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €19k more in shares than they have sold in the last 12 months.
공시 • May 07Biogaia AB (Publ) Approves DividendThe Annual General Meeting of BioGaia AB (publ) held on 6 May 2021, approved the dividend of SEK 3.41 per share.
Reported Earnings • May 06First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr202.0m (up 11% from 1Q 2020). Net income: kr50.4m (up 21% from 1Q 2020). Profit margin: 25% (up from 23% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Upcoming Dividend • Apr 30Upcoming dividend of kr3.41 per shareEligible shareholders must have bought the stock before 07 May 2021. Payment date: 14 May 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.1%). Higher than average of industry peers (0.5%).
Reported Earnings • Apr 04Full year 2020 earnings released: EPS kr10.07The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr747.1m (down 2.8% from FY 2019). Net income: kr179.7m (down 4.1% from FY 2019). Profit margin: 24% (in line with FY 2019). Post-clinical trial products Launched (during full year): 18 Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year.
Is New 90 Day High Low • Feb 20New 90-day low: €43.00The company is down 4.0% from its price of €44.70 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.41 per share.
Recent Insider Transactions • Feb 12CEO & President recently bought €9.8k worth of stockOn the 4th of February, Isabelle Valerie Ducellier bought around 220 shares on-market at roughly €44.43 per share. This was the largest purchase by an insider in the last 3 months. Isabelle Valerie has been a buyer over the last 12 months, purchasing a net total of €56k worth in shares.
Reported Earnings • Feb 06Full year 2020 earnings released: EPS kr10.07 (vs kr10.81 in FY 2019)The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr747.1m (down 2.8% from FY 2019). Net income: kr179.7m (down 4.1% from FY 2019). Profit margin: 24% (in line with FY 2019). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 06Revenue beats expectationsRevenue exceeded analyst estimates by 0.5%. Over the next year, revenue is forecast to grow 4.6%, compared to a 80% growth forecast for the Biotechs industry in Germany.
공시 • Nov 26BioGaia AB (publ) Elects Niklas Ringby as New Board MemberBioGaia AB (publ) announced at its Extraordinary General Meeting was held on 25 November 2020, the shareholders elected Niklas Ringby as new Board member.
Valuation Update With 7 Day Price Move • Nov 05Market bids up stock over the past weekAfter last week's 19% share price gain to kr48.90, the stock is trading at a trailing P/E ratio of 44.8x, up from the previous P/E ratio of 37.6x. This compares to an average P/E of 30x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 62%.
공시 • Oct 31BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion.BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion. Security Name: B Shares Security Type: Common Stock Securities Offered: 2,860,000 Price\Range: SEK 400
Reported Earnings • Oct 24Third quarter earnings releasedOver the last 12 months the company has reported total profits of kr193.8m, up 1.0% from the prior year. Total revenue was kr767.1m over the last 12 months, largely unchanged from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 24Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 29% at kr132.0m. Revenue is forecast to grow 18% over the next year, compared to a 301% growth forecast for the Biotechs industry in Germany.
Valuation Update With 7 Day Price Move • Oct 19Market pulls back on stock over the past weekAfter last week's 21% share price decline to kr44.05, the stock is trading at a trailing P/E ratio of 37.6x, down from the previous P/E ratio of 47.9x. This compares to an average P/E of 36x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 57%.
Is New 90 Day High Low • Oct 16New 90-day low: €43.55The company is down 17% from its price of €52.40 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.89 per share.
Valuation Update With 7 Day Price Move • Oct 16Market pulls back on stock over the past weekAfter last week's 18% share price decline to kr43.55, the stock is trading at a trailing P/E ratio of 38.1x, down from the previous P/E ratio of 46.4x. This compares to an average P/E of 36x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 55%.
공시 • Oct 05Biogaia Announces L. reuteri Protectis Reduces Pain in Children with Functional Abdominal PainIn a newly published systematic review and meta-analysis BioGaia AB (publ)'s L.reuteri Protectis (DSM 17938) was the only probiotic showing reduced pain intensity as well as an increased number of pain free days compared to placebo, in children with functional abdominal pain (FAP). Even if functional abdominal pain is a common gastrointestinal disorder, there are still no adequate treatment options available. The aim of the systematic review and meta-analysis was therefore to evaluate strain-specific probiotic effects on functional abdominal pain in children. The meta-analysis included nine studies, of which six were conducted with L. reuteri DSM 17938 and three with L. rhamnosus GG (LGG). The primary outcome, number of children with no symptoms at end of intervention, was however not reached.
공시 • Aug 14+ 1 more updateBioGaia AB (publ) to Report First Half, 2021 Results on Aug 12, 2021BioGaia AB (publ) announced that they will report first half, 2021 results on Aug 12, 2021